Relationship of serum lncRNA XIST and miR-30d-5p levels with diabetic peripheral neuropathy in type 2 diabetes

Am J Transl Res. 2022 Dec 15;14(12):9001-9006. eCollection 2022.

Abstract

Objective: To investigate the relationship between serum long non-coding RNA (lncRNA) X inactive specific transcript (XIST) and microRNA-30d-5p (miR-30d-5p) expression levels in type 2 diabetic peripheral neuropathy (DPN).

Methods: Clinical data of patients with only type 2 diabetes mellitus (pure T2DM group), DPN patients (DPN group) and healthy patients (control group) admitted to Inner Mongolia Forestry General Hospital from August 2019 to April 2022 were retrospectively analyzed, with 76 cases in each group. The serum lncRNA XIST and miR-30d-5p expression levels of each group were compared. The correlation between serum lncRNA XIST and miR-30d-5p in DPN patients was analyzed. The influencing factors of DPN occurrence were analyzed. Also, the diagnostic value of serum lncRNA XIST and miR-30d-5p for DPN was analyzed.

Results: There were significant differences in the lncRNA XIST and miR-30d-5p expression levels among the pure T2DM group, DPN group, and control group. LncRNA XIST expression level was negatively correlated with miR-30d-5p in DPN patients (P<0.05). Triglycerides, hemoglobin A1c, miR-30d-5p were risk factors for the occurrence of DPN, and lncRNA XIST was a protective factor (P<0.05). The areas under the curve (AUC) of serum lncRNA XIST and miR-30d-5p for the diagnosis of DPN were 0.851 and 0.845, respectively, and the AUC of lncRNA XIST and miR-30d-5p combined was 0.932, with a sensitivity of 92.1%, and a specificity of 85.5%.

Conclusion: Both lncRNA XIST and miR-30d-5p may be involved in the development of type 2 DPN. Therefore, detecting serum levels of both may be helpful for clinical diagnosis and treatment of type 2 DPN.

Keywords: MicroRNA-30d-5p; X inactive specific transcript; type 2 diabetic peripheral neuropathy.